Ropivacaine

Modify Date: 2024-01-02 07:15:11

Ropivacaine Structure
Ropivacaine structure
Common Name Ropivacaine
CAS Number 84057-95-4 Molecular Weight 274.401
Density 1.0±0.1 g/cm3 Boiling Point 410.2±45.0 °C at 760 mmHg
Molecular Formula C17H26N2O Melting Point 144 - 146ºC
MSDS N/A Flash Point 201.9±28.7 °C

 Use of Ropivacaine


Ropivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management[1].

 Names

Name (S)-ropivacaine
Synonym More Synonyms

 Ropivacaine Biological Activity

Description Ropivacain is a potent sodium channel blocker and acts as a local anesthetic agent. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of regional anesthesia and neuropathic pain management[1].
Related Catalog
Target

IC50: sodium ion influx[1] IC50: 402.7 μM (TREK-1 in COS-7 cell's membrane)[2]

In Vivo Epidural administration of Ropivacaine effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury[1]. Ropivacaine inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC)[2]. Ropivacaine prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats[2]. Ropivacaine inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs[2]. Animal Model: Adult Sprague-Dawley rats (300–400g)[1] Dosage: 1 μM Administration: Infusion (added to the perfusate reservoir) Result: Attenuated pressure-dependent increases in filtration coefficient (Kf).
References

[1]. Dene Simpson, et al. Ropivacaine: a review of its use in regional anaesthesia and acute pain management. Drugs. 2005;65(18):2675-717.

[2]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321.

[3]. Hye Won Shin, et al. The inhibitory effects of bupivacaine, levobupivacaine, and ropivacaine on K2P (two-pore domain potassium) channel TREK-1. J Anesth

[4]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.

 Chemical & Physical Properties

Density 1.0±0.1 g/cm3
Boiling Point 410.2±45.0 °C at 760 mmHg
Melting Point 144 - 146ºC
Molecular Formula C17H26N2O
Molecular Weight 274.401
Flash Point 201.9±28.7 °C
Exact Mass 274.204498
PSA 32.34000
LogP 3.11
Vapour Pressure 0.0±1.0 mmHg at 25°C
Index of Refraction 1.552
Storage condition -20℃

 Safety Information

Hazard Codes Xi
Risk Phrases R36/37/38:Irritating to eyes, respiratory system and skin .
Safety Phrases 36/37/39-26
WGK Germany 3
RTECS LK8650000
HS Code 2933399090

 Synthetic Route

~90%

Ropivacaine Structure

Ropivacaine

CAS#:84057-95-4

Literature: BRIDGE PHARMA, INC. Patent: WO2008/88756 A1, 2008 ; Location in patent: Page/Page column 34 ;

~93%

Ropivacaine Structure

Ropivacaine

CAS#:84057-95-4

Literature: L. MOLTENI and C. DEI FRATELLI ALITTI - SOCIETA DI ESERCIZIO S.P.A. Patent: WO2006/133837 A2, 2006 ; Location in patent: Page/Page column 3-4 ;

 Customs

HS Code 2933399090
Summary 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Synonyms

(S)-ROPIVACAINE HCL
(2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide
(S)-ROPIVACAINE HYDROCHLORIDE
(S)ROPIVACAINE HYDROCHLORIDE
(S)-ROPIVACAINEHYDROCHLORIDE
UNII-V910P86109
(S)-(-)-ropivacaine
(-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
Ropivacaine
Ropivacaine hydrochloride Monohydrate
(S)ROPIVACAINE HY DROCHLORIDE
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-, hydrochloride, hydrate (1:1:1)
S-ROPIVACAINE HCL
Ropivacaine (hydrochloride Monohydrate)
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide
Ropivacaine API
(+-)-ropivacaine hydrochloride
(S)-ROPIVACAINEHCL
(S)-(-)-1-propyl-2',6'-pipecoloxylidide
S-ROPIVACAINEHCL
ROPACARAINEHCL
MFCD00864425
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-
RopivacaineHcl/MesylateBase
Ropivacainehydrochloride
Naropin
Ropivacaine hydrochloride
(S)-(-)-1-propyl-2',6'-pipecoloxylidine hydrochloride monohydrate
l-N-n-Propylpipecolic acid-2,6-xylidide
ROPIVACAINE MESYLATER
(-)-1-Propyl-2',6'-pipecoloxylidide
UNII-7IO5LYA57N
(S)-ropivacaine hydrochloride hydrate
(S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide
Naropine
(S)-N-propylpiperidine-2-carboxylic acid 2,6-dimethylphenyl amide
ropivacaine hydrochloride hydrate
Ropivacaine HCl.H2O
Ropivacaine HCl
S-ROPIVACAINE HYDROCHLORIDE
(2S)-N-(2,6-Dimethylphenyl)-1-propyl-2-piperidinecarboxamide hydrochloride hydrate
(2S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride hydrate
Top Suppliers:I want be here



Get all suppliers and price by the below link:

Ropivacaine suppliers


Price: ¥450/10 mg

Reference only. check more Ropivacaine price